New Rochelle, NY, June 22, 2021 – Mary Ann Liebert, Inc., publishers and Genetic Engineering & Biotechnology News (GEN) announce the launch of GEN Biotechnology, a groundbreaking multidisciplinary peer-reviewed journal for exceptional research breakthroughs, news, and analysis directly impacting biotech.
GEN Biotechnology will provide a dynamic new peer-reviewed complement to GEN, the biotechnology industry’s flagship news publication that has covered the biotech industry for the past 40 years. GEN Biotechnology will complement the many preeminent biomedical journals in the Mary Ann Liebert, Inc. portfolio, including Human Gene Therapy, The CRISPR Journal, and Tissue Engineering.
The biotech industry is booming. New companies are being funded and going public on a weekly basis, and talented students and postdocs from leading research labs are increasingly moving to industry rather than staying in academia. Innovation continues to spark new therapeutic strategies and platforms. GEN Biotechnology will uniquely bring together both traditional academic audiences and executives and researchers from across the industry through exciting original research articles and reports, comprehensive review articles, news and analysis, interviews, and commentaries.
“For four decades, this company has prided itself on being a partner to the biotech industry through its expanding portfolio of peer-reviewed journals and the blanket coverage of Genetic Engineering & Biotechnology News. There has never been a more exciting time in biotech, as new technologies are poised to transform medicine. We couldn’t be more excited to introduce GEN Biotechnology to help validate those scientific and technological breakthroughs and become a vibrant and vital cog in the industry,” says Kevin Davies, PhD, Executive Vice President of GEN, founding editor of Nature Genetics, and Executive Editor of GEN Biotechnology.
“GEN has proudly served and reported on the biotech community since the inception of the industry 40 years ago. We’re excited to see our name and values carry over to help launch this thrilling new journal, and look forward to contributing to the success of GEN Biotechnology,” said John Sterling, editor-in-chief of GEN.
GEN Biotechnology will publish major advances across all aspects of basic and translational biotechnology research, including drug discovery, cell and gene therapy, immunotherapy, genome editing and writing, infectious diseases, artificial intelligence, agricultural biotechnology, bioengineering, neuroscience, cancer research, molecular diagnostics, the microbiome, and precision medicine. Each issue will also feature a critical mix of news/analysis stories and commentaries from key opinion leaders across the biotech industry.
GEN Biotechnology has begun to assemble a talented, diverse editorial board with expertise spanning all areas of editorial interest. A search for the chief editor is also underway. The Journal will shortly announce its initial call for research papers, with plans to publish a preview issue in 2021 and the inaugural issue in early 2022.
For further information, to sign up for email alerts, or to submit your manuscript, please contact us.
About Mary Ann Liebert, Inc.
Founded by Mary Ann Liebert in 1980, Mary Ann Liebert, Inc. is a leading independent publisher of scientific, technical, and medical content, known worldwide for its prescience and establishment of authoritative peer-reviewed journals, books, and trade publications in cutting-edge fields. Driven by her visionary passion and ceaseless curiosity, Mary Ann Liebert identifies and nurtures critical topics and cutting-edge fields by creating first-to-market publications that play a vital role in advancing research and facilitating collaboration in academia, industry, and government. For complete information, please visit the Mary Ann Liebert, Inc. website.
About Genetic Engineering & Biotechnology News (GEN)
Launched in 1981, GEN was the first publication in this field and remains the key driver in the explosion of the industry, paving the way for the development of new technologies and applications, investment growth, and career opportunities. With 40 years of publishing experience, GEN maintains unrivaled integrity, influence, and expertise that plays a pivotal role in driving the productivity and growth of the industry. For complete information, please visit the GEN website.